Publications by authors named "Christine K Bailey"
Article Synopsis
- The study compared the effectiveness of daprodustat, a new treatment for anemia in chronic kidney disease (CKD) patients on hemodialysis, with the standard treatment, epoetin alfa, in a noninferiority trial over 52 weeks.
- Results showed that daprodustat was as effective as epoetin in improving hemoglobin levels, with 80% of daprodustat patients responding adequately, compared to 64% with epoetin.
- Both treatments had similar rates of adverse events and impacts on blood pressure, while there was no significant difference in monthly intravenous iron use between the two groups.
Article Synopsis
- Daprodustat, a medication aimed at treating anemia in chronic kidney disease (CKD) patients undergoing hemodialysis, was studied for its effectiveness when given three times a week compared to standard daily doses.
- A total of 103 hemodialysis patients, with hemoglobin levels between 9.0 to 11.5 g/dL, were randomized to receive different doses of daprodustat or a placebo over 29 days.
- The results showed that daprodustat increased hemoglobin levels in a dose-dependent manner, was well tolerated, and established important dosing guidelines for further long-term studies in CKD treatment.
Background: The oral thrombopoietin receptor agonist eltrombopag is approved for treatment of adults with chronic immune thrombocytopenia. In the PETIT trial, we aimed to investigate the efficacy and safety of eltrombopag in children with persistent or chronic immune thrombocytopenia.
Methods: PETIT was a three-part, randomised, multicentre, placebo-controlled study done at 22 centres in the USA, UK, Canada, Spain, France, and the Netherlands.
Background: The thrombopoietin receptor agonist eltrombopag has been shown to be safe, tolerable, and effective for adults with chronic immune thrombocytopenia. We aimed to investigate the safety and efficacy of eltrombopag for children with chronic immune thrombocytopenia.
Methods: PETIT2 was a two part, randomised, multicentre, placebo-controlled study done at 38 centres in 12 countries (Argentina, Czech Republic, Germany, Hong Kong, Israel, Italy, Russia, Spain, Taiwan, Thailand, UK, and USA).
Thrombopoietin receptor agonists, which raise platelet counts in patients with chronic immune thrombocytopenia, may be associated with increases in bone marrow (BM) reticulin. Patients with chronic immune thrombocytopenia participating in the Eltrombopag Extended Dosing (EXTEND) study underwent BM biopsies to identify clinically relevant BM fibrosis-related increases. Specimens were centrally reviewed by 2 hematopathologists.
View Article and Find Full Text PDFPatients with chronic immune thrombocytopenia may have bleeding resulting from low platelet counts. Eltrombopag increases and maintains hemostatic platelet counts; however, to date, outcome has been reported only for treatment lasting ≤ 6 months. This interim analysis of the ongoing open-label EXTEND (Eltrombopag eXTENded Dosing) study evaluates the safety and efficacy of eltrombopag in 299 patients treated up to 3 years.
View Article and Find Full Text PDFArticle Synopsis
- Eltrombopag is an oral medication used to treat chronic idiopathic thrombocytopenic purpura and is a thrombopoietin receptor agonist.
- Two studies were conducted to evaluate how food and antacids affect the drug’s absorption and safety in healthy adults.
- Results showed that high-fat, high-calcium meals significantly reduced eltrombopag's bioavailability, while low-fat, low-calcium meals had minimal impact on absorption.
Spinal and bulbar muscular atrophy (SBMA) is one of a growing number of neurodegenerative diseases caused by a polyglutamine-encoding CAG trinucleotide repeat expansion, and is caused by an expansion within exon 1 of the androgen receptor (AR) gene. The family of polyglutamine diseases is characterized by the presence of ubiquitinated, intranuclear inclusions associated with molecular chaperones and 26S proteasome components, although the role of these inclusions in the pathogenesis of polyglutamine diseases remains unclear. The over-expression of molecular chaperones of the Hsp70 and Hsp40 families has been shown to modulate inclusion frequency and cellular toxicity.
View Article and Find Full Text PDF